

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims

1. (Previously presented) An isolated and purified having an amino acid sequence selected from the group consisting of:

RVVRVVRVVR (SEQ ID NO:4);

RRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 5);

VRRVRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 6);

RRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR
(SEQ ID NO:7);

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR
(SEQ ID NO:8);

RVVRVVRVVR (SEQ ID NO:9);

RRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:10);

VRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID
NO:11); and

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR
WRVV (SEQ ID NO:12).
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)

7. (Cancelled)

8. (Original) The peptide of claim 1 having the amino acid sequence:

RVVRVVRVVR (SEQ ID NO:4)

9. (Original) A composition comprising the peptide of claim 8 and a carrier.

10. (Original) The peptide of claim 1 having the amino acid sequence:

RRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 5).

11. (Original) A composition comprising the peptide of claim 10 and a carrier.

12. (Original) The peptide of claim 1 having the amino acid sequence:

VRRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 6).

13. (Original) A composition comprising the peptide of claim 12 and a carrier.

14. (Original) The peptide of claim 1 having the amino acid sequence:

RRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR
(SEQ ID NO:7);

15. (Original) A composition comprising the peptide of claim 14 and a carrier.

16. (Original) The peptide of claim 1 having the amino acid sequence:

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR
VRR (SEQ ID NO:8).

17. (Original) A composition comprising the peptide of claim 16 and a carrier.

18. (Original) The peptide of claim 1 having the amino acid sequence:

RVVRVVRVVR (SEQ ID NO:9).

19. (Original) A composition comprising the peptide of claim 18 and a carrier.

20. (Original) The peptide of claim 1 having the amino acid sequence:

RRVVRVVRVVRVVRVVRVVR (SEQ ID NO:10).

21. (Original) A composition comprising the peptide of claim 20 and a carrier.

22. (Original) The peptide of claim 1 having the amino acid sequence:

VRRVWRRVVRVRRWVRRVRRVWRRVVRVRRWVRR (SEQ ID

NO:11);

23. (Original) A composition comprising the peptide of claim 23 and a carrier.

24. (Original) The peptide of claim 1 having the amino acid sequence:

RVVRVRRWVRRVRRVWRRVVRVRRWVRRVRRVWRRVVRVRR

WRVV (SEQ ID NO:12).

25. (Original) A composition comprising the peptide of claim 24 and a carrier.

26. (Original) The peptide of claim 1 wherein said peptide has antimicrobial activity.

27. (Previously presented) The peptide of claim 1 wherein said peptide has

antimicrobial activity in a low salt medium.

28. (Previously presented) The peptide of claim 1 wherein said peptide has

antimicrobial activity in physiological salt.

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Previously presented) An isolated and purified lentiviral lytic peptide-1 peptide

analog-comprising an amino acid sequence selected from the group consisting of:

RVVRVRRVVRVRR (SEQ ID NO:4);

RRVRRVRRVRRVVRVRRVVRVRR (SEQ ID NO: 5);

VRRVVRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 6);

RRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR

(SEQ ID NO:7);

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRV

VRR (SEQ ID NO:8);

RVVRVVRVVRVVR (SEQ ID NO:9);

RRWVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:10);

VRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID

NO:11); and

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRV

WRVV (SEQ ID NO:12),

and at least one additional residue wherein said peptide analog comprises an
amphipathic α -helical structure.

35. (Previously presented) A solid phase substrate comprising at least one peptide

selected from the group consisting of:

RVVRVVRVVRVVR (SEQ ID NO:4);

RRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 5);

VRRVVRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 6);

RRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR

(SEQ ID NO:7);

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRV

VRR (SEQ ID NO:8);

RVVRVVRVVRVVR (SEQ ID NO:9);

RRWVRRVRRVWRRVVRVVRWVRR (SEQ ID NO:10);

VRRVWRRVVRVVRWVRRVRRVWRRVVRVVRWVRR (SEQ ID

NO:11); and

RVVRVVRWVRRVRRVWRRVVRVVRWVRRVRRVWRRVVRVVR

WRVV (SEQ ID NO:12).

36. (Original) The solid phase substrate of claim 35 wherein said solid phase substrate is a prosthetic device.

37. (Original) The solid phase substrate of claim 35 wherein the prosthetic device is a prosthetic joint.

38. (Previously presented) The peptide of claim 1 wherein said peptide further comprises at least one cysteine residue.

39. (Original) The peptide of claim 39 wherein said peptide is a disulfide linked dimeric peptide.

40. (Previously presented) An isolated and purified peptide-cargo complex comprising a cargo and a peptide selected from the group consisting of:

RVVRVVRVVR (SEQ ID NO:4);

RRVRRVRRVVRVVRVVRVVR (SEQ ID NO: 5);

VRRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:

6);

RRVRRVRRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR

(SEQ ID NO:7);

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR

VRR (SEQ ID NO:8);

RVVRVVRRWVRR (SEQ ID NO:9);

RRWVRRVRRVWRRVVRVVRRWVRR (SEQ ID NO:10);

VRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRRWVRR (SEQ ID

NO:11); and

RVVRVVRRWVRRVRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRR

WRVV (SEQ ID NO:12).

41. (Original) The peptide-cargo complex of claim 40 wherein said peptide has antimicrobial activity and said cargo increases the antimicrobial activity of said peptide.

42-65 (Cancelled)

Please cancel claims 29-33.